Introduction {#sec0005}
============

*Porphyromonas gingivalis* was previously known as *Bacteroides gingivalis*, and renamed *P. gingivalis* after numerous rounds of taxonomic reclassification. *P. gingivalis* is a gram-negative anaerobic bacterium, said to be frequently detected in dental plaque \[[@bib0010]\].

While skin infections caused by *Bacteroides* and *Prevotella*, from the same taxonomic class, play a significant role in post-operative infections, infections caused by *Porphyromonas* are considered rare. Skin abscesses have known involvement with aerobic and anaerobic bacteria, including *Streptococcus anginosus*, *Streptococcus pyogenes*, and *Staphylococcus aureus*, all of which are common causes of skin infections \[[@bib0005],[@bib0015]\]. However, *Porphyromonas* species are more commonly associated with oral infections \[[@bib0010]\].

In this case study, we describe the onset and treatment of a skin abscess caused by *P. gingivalis* in a 67-year-old man who was undergoing chemotherapy for lung cancer. Drainage of the abscess via skin incision and treatment with antibioticss resulted in satisfactory resolution.

Case Report {#sec0010}
===========

A 67-year-old man attended the Dermatology Department at JR Tokyo General Hospital with swelling to the left side of his head. He had commenced chemotherapy (weekly Paclitaxel \[80 mg/m^2^\] + Carboplatin \[300 mg/m^2^\], the 1^st^ line regimen used for lung cancer.) for lung cancer cT3N3M0 stage Ⅲ B three days prior to his consultation with Dermatology. Clinical examination revealed a fist-sized mass with a hot sensation to the left temporal region of the face. Initial laboratory workup on the day of consultation showed an elevated serum C-reactive protein level of 416 nmol/L. The patient was diagnosed with a skin infection and started on cefazolin at 6 g/day, but his symptoms did not improve. Therefore drainage via skin incision was performed three days later, and the exudate was collected and submitted for laboratory culture. Cefazolin at 6 g/day was continued, along with treatment of the wound, and *P. gingivalis* was detected from the pus culture. Sensitivity of the bacteria to various antibioticss is shown in [Table 1](#tbl0005){ref-type="table"}. The patient's symptoms improved within one month, and chemotherapy was resumed.Table 1Antibacterial sensitivity test report of *P. gingivalis* cultured from exudate collected from the patient's lesion.Table 1DrugMIC[1](#tblfn0005){ref-type="table-fn"}InterpretationAmoxicillin≤0.06S^2^Piperacillin≤0.03SCefazolin≤0.12SGentamicin≤0.12SArbekacin1R^3^Clarithromycin≤0.12SClindamycin\>4RMinocycline0.5SFosfomycin≤4SVancomycin≤1NA^4^Levofloxacin\>8R[^1]

Discussion {#sec0015}
==========

This patient experienced a skin abscess caused by *P. gingivalis.* While this is a common cause of oral infections, it is thought to infect the skin and other systems only rarely \[[@bib0010]\]. Due to undergoing treatment for lung cancer, the patient was considered immunocompromised \[[@bib0020]\]. Unfortunately, as the exudate culture was submitted after administration of cefazolin, it is not known whether other causative bacteria could have been involved. However, formation of the abscess and detection of cefazolin-sensitive *P. gingivalis* only, with no other pathogens, suggests that *P. gingivalis* was the likely cause. Additionally, the patient uses dentures, which may be a contributing factor for *P. gingivalis* activity.

There has been suggestion of *P. gingivalis* involvement in oral cancer \[[@bib0025]\], but its association with lung cancer has not been reported and remains unknown. No skin infection or skin abscess due to *P. gingivalis* is reported within the PubMed search range, and this case is considered to be the first of skin abscess due to *Porphyromonas gingivalis*.
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[^1]: MIC: minimum inhibitory concentration; ^2^S: sensitive; ^3^R: resistant; ^4^NA: not assessed.
